• There were no items above the 0.70 criteria for inter-item correlation in either study, indicating that each item contributed independently to the RASQ total score. However, there were multiple internal consistency values exceeding the 0.70 criteria in each study (PrefMab, alpha = 0.833; MabCute, alpha = 0.826) . Factor analysis indicated that the RASQ is a multidimensional scale with four potential domains (Eigenvalue >1.0).
Baseline characteristics
• Patient baseline demographics and disease characteristics were well balanced between treatment arms in PrefMab.
-Median age was 60 (18-80) years and most (62%; n=268) patients had DLBCL, commonly low (35%), lowintermediate (24%), or high-intermediate (24%) risk by IPI classification. Of patients with FL, 36% and 39% had intermediate-and high-risk disease, respectively.
-Most patients had an ECOG performance status of 0 (60%) or 1 (34%).
-The most common regimens for patients with DLBCL were R-CHOP-216 (43%), R-CHOP-218 (43%), and R-CHOP-14 6 (10%). The most common regimens for FL were R-bendamustine-28 6 (36%), R -CHOP-21 6 (29%), and R-CVP-218 (13%).
• Median age in MabCute was 64.5 (20-90) years and the most common type of iNHL was FL (60.6%), with 32.8% and 35.9% of patients having FLIPI intermediate-or high-risk disease, respectively.
-The majority of patients received R-bendamustine as induction chemotherapy (63.4%).
RASQ results
• Median RASQ scores for PrefMab and MabCute are shown in Figure 2 . In PrefMab, results were similar irrespective of sequence of rituximab formulation. 
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• Rituximab (MabThera ® , Rituxan ® ; F. Hoffmann-La Roche Ltd) in combination with chemotherapy is standard of care for both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
-Rituximab is a chimeric monoclonal antibody that specifically binds to CD20 on the surface of B lymphocytes. 1
• A subcutaneous (SC) formulation of rituximab (MabThera SC) has been developed to improve patient convenience and reduce healthcare burden without compromising clinical activity. 2, 3 -Rituximab intravenous (IV) infusion can take 1.5-6 hours to complete, 4 requires patient monitoring throughout, and represents the longest part of the treatment cycle. In contrast, rituximab SC reduces administration times (approximately 5 minutes) compared with the IV route.
-A recent time and motion study showed that over the first year of treatment for a single patient (eight induction and three maintenance administrations) the estimated reduction in patient chair time associated with a switch from IV to SC rituximab ranged from 31 hours (Austria and France) to 60 hours (Italy). 5
• The phase Ib SparkThera study showed that in FL, a fixed dose of rituximab SC 1,400 mg was pharmacokinetically non-inferior to rituximab IV, achieving non-inferior C trough levels compared with IV at the established non-Hodgkin's lymphoma (NHL) maintenance dose of 375 mg/m 2 (for both the 2-monthly and 3-monthly regimens). 2 -Subsequently, stage 1 of the phase III SABRINA study confirmed that C trough with rituximab SC 1,400 mg was non-inferior to rituximab IV (375 mg/m 2 ) given every 3 weeks as part of NHL induction therapy. 3
• The Rituximab Administration Satisfaction Questionnaire (RASQ) was developed to assess patients' perceptions of the impact of route of administration, and their satisfaction with rituximab SC (RASQ-SC) or IV (RASQ-IV).
-The RASQ demonstrated strong conceptual validation during concept elicitation and cognitive debriefing interviews for patients (n=10) with NHL, showing excellent coverage of concepts relevant to patients' own treatment experiences (Data on file, F. Hoffmann-La Roche Ltd).
-In addition, patients found the response options easy to understand and respond to.
• The aims of the current analysis were to examine the extent of patient preference for rituximab SC versus IV in the phase IIIb PrefMab and MabCute studies using the RASQ, and to explore the psychometric validity of the RASQ.
PrefMab and MabCute studies
• Eligibility for enrolment in PrefMab (NCT01724021) and MabCute (NCT01461928) was as follows: -MabCute: aged ≥18 years with relapsed or refractory CD20+ indolent NHL (iNHL; grade 1-3a) following ≥1 line of immunotherapy and/or chemotherapy, and/or radiotherapy; ECOG performance status ≤2.
• Study designs for PrefMab and MabCute are shown in Figure 1 . All patients provided written informed consent. • Consistent patient satisfaction and preference for rituximab SC versus rituximab IV was demonstrated in the PrefMab and MabCute studies.
• Psychometric analyses showed that RASQ is a reliable and valid measure of patient treatment preferences.
• These data indicate patients' preference for rituximab SC compared with rituximab IV, despite the fact that chemotherapy is administered IV in the induction setting. • In PrefMab, patients received one cycle of rituximab IV (375 mg/m 2 ) followed by either rituximab SC (1400 mg 3) then rituximab IV (4), or rituximab IV (3) then rituximab SC (4), with chemotherapy.
-Chemotherapy was CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CVP (cyclophosphamide, vincristine, prednisone), or bendamustine.
-In PrefMab the RASQ was completed at cycles 4 and 8. • In PrefMab, a higher proportion of patients felt that the amount of time taken for administration of rituximab was 'just right' among those who had received their most recent dose as rituximab SC, compared with rituximab IV (87.5% versus 48.7%, respectively). In addition, more patients felt that rituximab IV administration took 'too long' compared with rituximab SC (47.4% PrefMab; 55.4% MabCute).
• The shorter administration time with rituximab SC (approximately 5 minutes) did not considerably affect patients' satisfaction with their ability to spend time talking with their nurse or doctor (Figure 3 ).
• RASQ responses indicated that patients preferred rituximab SC over the IV route.
-In PrefMab, SC administration was preferred by 80.3% and 85.9% of patients with IV or SC as most recent dose, respectively.
• In MabCute, patients received induction rituximab IV (375 mg/m 2 ; one cycle) then rituximab SC (1,400 mg; cycles 2-8) plus 6-8 chemotherapy cycles.
-Chemotherapy was bendamustine, CHOP, CVP, FCM (fludarabine, cyclophosphamide, and mitoxantrone), MCP (mitoxantrone, chlorambucil, and prednisone), CHVP-IFN (cyclophosphamide, doxorubicin, etoposide, prednisolone, and interferon), chlorambucil, any fludarabine-containing regimen (including oral fludarabine), or GIFOX (gemcitabine, oxaliplatin, and ifosfamide).
-In MabCute the RASQ was completed during induction at visits 3 (RASQ-IV) and 6 (RASQ-SC).
• The RASQ was completed after rituximab but before chemotherapy administration in both studies.
RASQ instrument
• The clinical data cut off for the RASQ analysis was 5 September 2013. Questionnaire responses were summarised using the intent-to-treat population, which comprised all randomised patients (PrefMab, n=419; MabCute, n=92).
-Questionnaire responses were assessed using descriptive statistics.
• Preliminary item analysis was conducted on the RASQ utilising data from the PrefMab and MabCute datasets at visit 4 and cycle 3, respectively. Given the mixed rating scales contained in the instrument, frequency distributions were evaluated for each item.
-Inter-item correlation statistics were evaluated, with itempairs exhibiting a correlation >0.70 flagged for potential deletion.
-Internal consistency reliability was evaluated using Cronbach's Alpha with a threshold criteria of >0.70 for demonstrating reliability.
-Factor analysis was utilised to assess the degree to which these data conformed to the qualitative conceptual framework. 
Maintenance 2
Off-treatment follow-up until the end of the study -patients with PD will be followed for survival, and patients with SD will be followed for PD and survival 
